Robin Bhatt

Robin Bhatt specializes in angiosarcoma, one of the rarest and most aggressive vascular sarcomas. His clinical research has evaluated anti-angiogenic agents including pazopanib and axitinib in angiosarcoma as well as taxane-based regimens. He has studied radiation-induced secondary angiosarcoma of the breast and characterized its molecular features distinct from primary angiosarcoma. His work advocates for international cooperative group trials to generate evidence for this rare malignancy.